Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapiglutide - Zealand Pharma

Next Previous
Search
Drug Profile

Dapiglutide - Zealand Pharma

Alternative Names: Dual GLP-1R/GLP-2R agonist - Zealand Pharma; Dual-acting peptide therapeutic - Zealand Pharma; Dual-GLP-1/GLP-2 acting peptide - Zealand Pharma; GLP-1/GLP-2 receptor agonist - Zealand Pharma; ZP-7570

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Class Obesity therapies; Peptides
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity
  • No development reported Gastrointestinal disorders; Short bowel syndrome

Most Recent Events

  • 11 Feb 2025 Zealand Pharma terminates phase I trial in Obesity (In volunteers) in Germany (SC), due to sponsor decision(NCT06000891)
  • 23 Dec 2024 Zealand Pharma initiates a phase I trial for Obesity in Germany (SC) (NCT06758583)
  • 09 Sep 2024 Efficacy and adverse events data from the phase II trial in Obesity presented at 60th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top